{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:00:19Z","timestamp":1774008019897,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.ejca.2010.11.024","type":"journal-article","created":{"date-parts":[[2011,2,15]],"date-time":"2011-02-15T15:25:10Z","timestamp":1297783510000},"page":"683-689","source":"Crossref","is-referenced-by-count":88,"title":["Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809"],"prefix":"10.1016","volume":"47","author":[{"given":"C.L.","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Hars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Archer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Weckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kirshner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Sikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.J.","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hudis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Schilsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Paskett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2010.11.024_b0005","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00002018-200528050-00004","article-title":"Chemotherapy-induced ovarian failure: manifestations and management","volume":"28","author":"Molina","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.ejca.2010.11.024_b0010","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1634\/theoncologist.11-2-96","article-title":"The Influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors","volume":"11","author":"Knobf","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2010.11.024_b0015","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.23071","article-title":"Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function","volume":"110","author":"Oktem","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.11.024_b0020","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1200\/JCO.2007.14.1655","article-title":"Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility","volume":"26","author":"Schover","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.11.024_b0025","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/01.gco.0000233937.36554.d3","article-title":"Premature ovarian failure","volume":"18","author":"Meskhi","year":"2006","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.ejca.2010.11.024_b0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1196\/annals.1429.023","article-title":"Cancer treatment and the ovary: the effects of chemotherapy and radiation","volume":"1135","author":"Cohen","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.ejca.2010.11.024_b0035","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.11.024_b0040","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mpo.10341","article-title":"Management of osteoporosis due to ovarian failure","volume":"41","author":"Eastell","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ejca.2010.11.024_b0045","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","article-title":"Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2years of goserelin or 6months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)","volume":"14","author":"Fogelman","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ejca.2010.11.024_b0050","doi-asserted-by":"crossref","first-page":"6309s","DOI":"10.1158\/1078-0432.CCR-06-0652","article-title":"Skeletal complications of breast cancer therapies","volume":"12","author":"Hirbe","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2010.11.024_b0055","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","article-title":"Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group","volume":"34","author":"Reid","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2010.11.024_b0060","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230","volume":"26","author":"Eastell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.11.024_b0065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.maturitas.2008.03.008","article-title":"Effect of natural early menopause on bone mineral density","volume":"59","author":"Francucci","year":"2008","journal-title":"Maturitas"},{"key":"10.1016\/j.ejca.2010.11.024_b0070","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/gme.0b013e31804c793d","article-title":"Effect of early menopause on bone mineral density and fractures","volume":"14","author":"Gallagher","year":"2007","journal-title":"Menopause"},{"key":"10.1016\/j.ejca.2010.11.024_b0075","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","article-title":"Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.11.024_b0080","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1200\/JCO.2008.19.1783","article-title":"Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer","volume":"27","author":"Hines","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.11.024_b0085","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1210\/jc.2004-1444","article-title":"Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial","volume":"90","author":"Fuleihan Gel","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2010.11.024_b0090","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","article-title":"Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer","volume":"90","author":"Powles","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2010.11.024_b0095","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.11.024_b0100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2307\/2529944","article-title":"Allocation of patients to treatment in clinical trials","volume":"35","author":"Pocock","year":"1979","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2010.11.024_b0105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0021-9681(74)90015-0","article-title":"The randomization and stratification of patients to clinical trials","volume":"27","author":"Zelen","year":"1974","journal-title":"J Chron Dis"},{"key":"10.1016\/j.ejca.2010.11.024_b0110","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0197-2456(99)00017-3","article-title":"Data monitoring committees and interim monitoring guidelines","volume":"20","author":"Freidlin","year":"1999","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ejca.2010.11.024_b0115","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1172\/JCI113523","article-title":"Age and bone mass as predictors of fracture in a prospective study","volume":"81","author":"Hui","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2010.11.024_b0120","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","article-title":"A high incidence of vertebral fracture in women with breast cancer","volume":"79","author":"Kanis","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.11.024_b0125","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","article-title":"Fracture risk increases after breast cancer survivors","volume":"165","author":"Chen","year":"2005","journal-title":"Arch Int Med"},{"key":"10.1016\/j.ejca.2010.11.024_b0130","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1592\/phco.29.3.305","article-title":"Osteoporosis risk in premenopausal women","volume":"29","author":"Vondracek","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejca.2010.11.024_b0135","first-page":"55","article-title":"Premenopausal osteoporosis","volume":"99","author":"Bischoff","year":"2008","journal-title":"Minerva Med"},{"key":"10.1016\/j.ejca.2010.11.024_b0140","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00198-004-1677-3","article-title":"Special report on the official positions of the International Society for Clinical Densitometry","volume":"15","author":"Lewiecki","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ejca.2010.11.024_b0150","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10549-008-9937-0","article-title":"Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial","volume":"115","author":"Swain","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2010.11.024_b0155","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2005.05.3694","article-title":"Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.11.024_b0160","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.11.024_b0165","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","article-title":"Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status","volume":"24","author":"Vehmanen","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.11.024_b0170","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2010.11.024_b0175","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1158\/1078-0432.CCR-07-0247","article-title":"Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid","volume":"13","author":"Brown","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.11.024_b0180","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10549-004-2625-9","article-title":"Baseline bone mineral density of the total spine may predict for chemotherapy-induced ovarian failure","volume":"90","author":"Shapiro","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2010.11.024_b0185","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2010.11.024_b0190","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910011470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910011470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T20:51:15Z","timestamp":1543956675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910011470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0959804910011470"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.11.024","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}